Apellis Pharmaceuticals (APLS) 10-Q2023 Q1 Quarterly report

Filed: 4 May 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: adeno, Aid, appointed, assumption, average, Board, California, Canada, chose, Codification, decision, default, Department, Deposit, discontinue, employer, ERC, exceed, excessive, FDIC, impairment, individually, investor, lieu, light, manner, obsolete, receivership, recommendation, refund, refundable, released, Relief, retention, social, SVB, SYFOVRE, taxable, Trust, unblinded, undergo, validation, warrant

Removed: academic, adult, advancing, AG, age, annually, array, assessing, assuming, attractive, autoimmune, began, begun, blinded, breakthrough, calibrated, clinically, comparable, consistent, contingency, continually, continuing, decreased, decreasing, demonstrate, demonstrating, discounted, dose, dosed, efficacy, enrolled, executed, expertise, extrafoveal, FILLY, forfeiture, foveal, frequency, Germany, Hedging, holding, implied, increasing, inflammatory, interfering, key, kidney, lead, leadership, lesion, leveraging, longer, meaningful, meeting, month, monthly, multiple, Nasdaq, native, NDA, NOBLE, older, omicron, ophthalmology, pandemic, patient, Pipeline, placebo, pooled, premium, present, priority, production, ratio, reclassified, recurrence, recurrent, reducing, reduction, registrational, remeasurement, remotely, reopened, request, retinal, RNA, rollforward, scenario, schedule, sham, showed, showing, siRNA, situation, small, sporadic, strict, team, temporarily, transplant, type, unamortized, unrealized, utilization, VALIANT, variability, vision, wave, work, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated APLS transcripts

APLS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Apellis Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Timothy Sullivan, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 4, 2023	By:	/s/ Timothy Sullivan
		Timothy Sullivan
		Chief Financial Officer and Treasurer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.